Granted Patent
B2
US 12,453,718 · App. 18/538,443 · Granted Oct 28, 2025
Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug
Assignee:
CORXEL PHARMACEUTICALS HONG KONG LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A drug used for treating or preventing cerebral hemorrhage, the drug including, as an active ingredient, a compound represented by the following Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof:
Claims (19)
1. A method of reducing or suppressing a cerebral hemorrhage in a subject, the method comprising administering SMTP-7, or a pharmaceutically acceptable salt thereof, wherein the administering reduces neuronal damage, inflammation, or apoptosis in the subject.
2. The method according to claim 1 , wherein the SMTP-7 or a pharmaceutically acceptable salt thereof is SMTP-7.
3. The method according to claim 1 , wherein the cerebral hemorrhage is intracerebral hemorrhage.
4. The method according to claim 1 , wherein the SMTP-7 or a pharmaceutically acceptable salt thereof is administered intracerebrally.
5. The method according to claim 1 , wherein the cerebral hemorrhage does not associate with a cerebral infarction.
6. The method according to claim 1 , wherein reducing or suppressing cerebral hemorrhage is independent of reducing or suppressing cerebral infarction.
7. The method according to claim 2 , wherein the cerebral hemorrhage is intracerebral hemorrhage.
8. The method according to claim 2 , wherein SMTP-7 is administered intracerebrally.
9. The method according to claim 2 , wherein the cerebral hemorrhage does not associate with a cerebral infarction.
10. The method according to claim 2 , wherein reducing or suppressing cerebral hemorrhage is independent of reducing or suppressing cerebral infarction.
11. The method according to claim 1 , wherein the administering reduces apoptosis.
12. The method according to claim 11 , wherein the apoptosis is contralateral.
13. The method according to claim 11 , wherein the apoptosis is ipsilateral.
14. The method according to claim 1 , wherein the administering reduces neuronal damage.
15. The method according to claim 1 , wherein the administering reduces inflammation.
16. The method according to claim 1 , wherein the administering improves learning ability.
17. The method according to claim 1 , wherein the administering improves motor performance.
18. The method according to claim 2 , wherein the administering improves learning ability.
19. The method according to claim 2 , wherein the administering improves motor performance.
Assignments (4)
CHANGE OF NAME
Recorded Dec 4, 2024
From: JI XING PHARMACEUTICALS HONG KONG LIMITED
To: CORXEL PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 069492/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 30, 2024
From: BIOGEN MA INC.
To: JI XING PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 066379/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 13, 2023
From: TOMINAGA, TEIJI; NIIZUMA, KUNIYASU
To: TMS CO., LTD.
Reel/Frame 065989/0700 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 13, 2023
From: TMS CO., LTD.
To: BIOGEN MA INC.
Reel/Frame 065860/0348 →
Continuity (2)
References Cited (88)
US 7361493B1
· Hammond et al.
· 2008
[cited by applicant]
US 9078880B2
· Honda et al.
· 2015
[cited by applicant]
US RE47684E
· Kazuo et al.
· 2019
[cited by applicant]
US RE49351E
· Honda et al.
· 2023
[cited by applicant]
US 20050234063A1
· Terai et al.
· 2005
[cited by applicant]
US 20090270476A1
· Hasumi et al.
· 2009
[cited by applicant]
CN 101346471A
· 2009
[cited by applicant]
EP 2452679A1
· 2012
[cited by applicant]
JP 2002065288A
· 2002
[cited by applicant]
JP 2004224737A
· 2004
[cited by applicant]
JP 2004224738
· 2004
[cited by applicant]
JP 2008201688
· 2008
[cited by applicant]
JP 2009132724A
· 2009
[cited by applicant]
JP 2009215216A
· 2009
[cited by applicant]
JP 2019209932A
· 2019
[cited by applicant]
WO 2004002488A1
· 2004
[cited by applicant]
WO 2007040082A1
· 2007
[cited by applicant]
WO 2007094071
· 2007
[cited by applicant]
WO 2007111203
· 2007
[cited by applicant]
WO 2011125930A1
· 2011
[cited by applicant]
WO 2011004620A1
· 2012
[cited by applicant]
Matsumoto, Journal of Biological Chemistry (2014), 289(52), 35826-35838.
[cited by examiner]
West, Solid State Chemistry and Its Applications, john Wiley & Sons, 1984.
[cited by examiner]
Wolff, Burger's medicinal Chemistry and Drug Discovery, vol. 1, Principles and Practice, John Wiley & sons, New York, 1997.
[cited by examiner]
Shi et al., “Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled Trials”, Scientific Reports, 2016, vol. 6,33989, 8 pages.
[cited by applicant]
Kvistad et al., “Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke Results from NOR-TEST”, Stroke, 2019, vol. 50, No. 5, pp. 1279-1281.
[cited by applicant]
Shibata et al., “A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice”, Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, vol. …
[cited by applicant]
Sawada et al., “SMTP-7, a Novel Small-Molecule Thrombolytic for Ischemic Stroke: A Study in Rodents and Primates”, Journal of Cerebral Blood Flow & Metabolism, 2014, vol. 34, Issue 2, pp. 235-241.
[cited by applicant]
Suzuki et al., “Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys”, Pharmacology Research & Perspectives, 2018, vol. 6, No. 6, e00448, 10 pages.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US2022/028488 dated Sep. 8, 2022.
[cited by applicant]
Building a Stroke Portfolio, presentation slides dated Jun. 28, 2018.
[cited by applicant]
Adams et al. (May 2007) “Guidelines for the Early Management of Adults with Ischemic Stroke”, Stroke, pp. 1655-1711.
[cited by applicant]
Adams et al. (1996) “Guidelines for Thrombolytic Therapy for Acute Stroke: A Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke, A Statement for Healthcare Professionals from a Specia…
[cited by applicant]
Adibhatla et al., Jun. 2008, “Tissue Plasminogen Activator (IPA) and Matrix Metalloproteinases in the Pathogenesis of Stroke: Therapeutic Strategies”, CNS Neurol Disord Drug Targets, 7(3), pp. 243-253.
[cited by applicant]
Benakis et al., 2009, “Inflammation and stroke”, Kardiovaskulare Medizin, 12(5), pp. 143-150.
[cited by applicant]
Cheng et al., Jan. 2004, “Neuroprotection for Ischemic Stroke: Two Decades of Success and Failure”, The Journal of the American Society for Experimental NeuroTherapeutics, vol. 1, pp. 36-45.
[cited by applicant]
Cuadrado et al., Jul. 2008, “Tissue pasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release”, Journal of Leukocyte Biology, vol. 84, pp. 207-214.
[cited by applicant]
Donnan, Geoffrey A., Jan. 2008, “A New Road Map for Neuroprotection”, The 2007 Feinberg Lecture, pp. 242-248.
[cited by applicant]
Hu et al. (2000) “Activation of Fibrinolysis by SMTP-7 and -8, Novel Staplabin Analogs with a Pseudosymmetric Structure”, The Journal of Antibiotics, vol. 53, No. 3, Mar. 2000, pp. 241-247.
[cited by applicant]
Internet Stroke Center on the Wayback Machine http//:www.strokecenter.org.80/pat/ais.thm, “About Stroke”, copyright 1997-2002.
[cited by applicant]
Nozawa et al. (1997) “Stachybotrin C and Parvisporin, Novel Neurotogenic Compounds I. Taxonomy, Isolation, Physico-chemical and Biological Properties, The Journal of Antibiotics”, vol. 50, No. 8, (1997), pp. 635-640.
[cited by applicant]
Sacchetti, Maria Luisa, Jun. 2008, “Is it Time to Definitely Abandon Neuroprotection in Acute Ischemic Stroke”, Stroke, pp. 1659-1660.
[cited by applicant]
Terr (2001) “Strachybotrys: relevance to human disease,”Annals of Allergy, Asthma and Immunology, Dec. 2001, vol. 87, pp. 57-62.
[cited by applicant]
Longa et al., “Reversible Middle Cerebral Artery Occulsion Without Cranlectomy in Rats”, Stroke, 1989, vol. 20, No. 1, pp. 84-91.
[cited by applicant]
Kito et al., “Experimental thromboembolic stroke in cynomolgus monkey”, Journal of Neuroscience Methods, 2001, vol. 105, pp. 45-53.
[cited by applicant]
Chinese Patent Office Action for Chinese AppIn. Serial No. 201080030009.7, issued Jan. 14, 2013, 10 pages—English.
[cited by applicant]
EP. Pat. Appln. Serial No. 10796931.3, European Search Report mailed Nov. 2, 2012, 6 pages—English.
[cited by applicant]
Kilic et al., “Aggravation Of focal cerebral Ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor but does not depend on endothelial NO synthase”, Stroke, vol…
[cited by applicant]
Maeda et al., “A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: Increased neuroprotective efficacy and extended therapeutic time w…
[cited by applicant]
PCT/JP2010/051711, Written Opinion of IPEA dated filed Feb. 15, 2011, 6 pgs—Japanese; 7 pgs—English, Cert. of Trans.
[cited by applicant]
PCT/JP2010/051711, International Search Report , dated Mar. 23, 2010, 2 pgs.—Japanese; 2 pgs.—English.
[cited by applicant]
Kano et al. “Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke”, Brain Research, 2000, vol. 854, pp. 245-248.
[cited by applicant]
Takayasu et al., “Enhancement of fibrin binding and activation of plasminogen by staplabin through induction of a conformational change in plasminogen”, FEBS Letters, 1997, vol. 418, pp. 58-62.
[cited by applicant]
Huang et al., “Development and Validation of Oxygen Radical Absorbance Capacity Assay for Lipophillic Antioxidants Using Randomly Methylated [beta]-Cyclodextrin as a Solubility Enhancer”, Journal of Agricultural and Foo…
[cited by applicant]
Kohyama et al., “SMTP-1 and -2, Novel Analogs of Staplabin Produced by Stachybotrys Microspora”, The Journal of Antibiotics, 1997, vol. 50, No. 2, pp. 172-174.
[cited by applicant]
Hasumi et al., “Isolation of SMTP-3, 4, 5 and -6 Novel Analogs of Staplabin and their Effects on Plasminogen Activation and Fibrinolysis”, The Journal of Antibiotics, vol. 51, No. 12, 1998, pp. 1059-1068.
[cited by applicant]
Shinohara et al., “Staplabin, a Novel Fungal Triprenyl Phenol which stimulates the Binding of Plasminogen to Fibrin and U937 Cells”, The Journal of Antibiotics, 1996, vol. 49, No. 10, pp. 961-966.
[cited by applicant]
Nakagawara et al., “Treatment strategy for Acute Stage Cerebral Stroke Thrombolytic Therapy for Cardiogenic Cerebral Embolism”, Medicina, 2000, vol. 37, No. 7, pp. 1114-1116.
[cited by applicant]
Yoneda et al., “Feature Article: Treatment of Acute Stage Cerebral Infarction Drug Therapy in Acute Stage”; Geriatric Medicine, 1998, vol. 36, No. 5, pp. 679-684.
[cited by applicant]
The Lancet, vol. 363, Mar. 6, 2004, www.thelancet.com, “Association of outcome with early stoke treatment; pooled analysis of Atlantis, ECASS, and NINDS rt-PA stroke trials”, pp. 768-774.
[cited by applicant]
Hacke et al., Randomised double blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke: (ECASS II), The Lancet, vol. 352, Oct. 17, 1998, pp. 1245-1251.
[cited by applicant]
Matsumoto et al., “Soluble Epoxide Hydrolase as an Anti-Inflammatory Target of the Thrombolytic Stroke Drug SMTP-7”, The Journal of Biological Chemistry, 2014, vol. 289, No. 52, pp. 35826-35838.
[cited by applicant]
Gravanis et al., “tPA as a therapeutic target in stroke”, Expert Opin. Ther. Targets, 2008, vol. 12, No. 2.
[cited by applicant]
Partridge, “Building a Better Clot-Buster: rt-PA and Combination Therapy”, Psychiatric Times, 2007, 7 pages.
[cited by applicant]
Donnan et al., “Stroke”, The Lancet, 2008, vol. 371, pp. 1612-1623.
[cited by applicant]
Ito et al., “SMTP-7, a new thrombolytic agent, decreases hemorrhagic transformation after transient middle cerebral artery occulusion under warfarin anticoagulation in mice”, Brain Research, 2014, vol. 1578, pp. 38-48.
[cited by applicant]
Types of Stroke, last reviewed on Oct. 23, 2012, available at http:www.strokeassociation.org/STROKEORG/AboutStroke/TypesofStroke/Types-of-Stroke_UCM_308531_SubHomePage.jsp.
[cited by applicant]
Lansberg et al., “Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a meta-analysis”, Stroke, 2009, vol. 40, No. 7, pp. 2438-2441.
[cited by applicant]
Shibata et al., “Evaluation of the effects of a new series of SMTPs in the acetic acid-Induced embolic cerebral infarct mouse model”, European Journal of Pharmacology, 2017, vol. 818, pp. 221-227.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/IB2020/061485 dated Jan. 26, 2021.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/JP2020/044574 dated Jan. 26, 2021.
[cited by applicant]
West, “Solid State Chemistry and Its Applications”, John Wiley & Sons, 1984, pp. 365.
[cited by applicant]
Wolff, “Burger's medicinal Chemistry and Drug Discovery”, Fifth Edition, vol. 1, Principles and Practice, John Wiley & Sons, New York, 1997, pp. 975-977.
[cited by applicant]
Huang et al., “Reduction of Ischemia Reperfusion-Related Brain Hemorrhage by Stachybotrys Microspora Triprenyl Phenol-7 in Mice with Antioxidant Effects”, Journal of Stroke and Cerebrovascular Diseases, 2018, vol. 27, N…
[cited by applicant]
Office Action Issued in EA Application No. 202291522, dated May 22, 2023.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US2022/025462 dated Jul. 29, 2022.
[cited by applicant]
Huang et al., “Antineuroinflammatory Effect of SMTP-7 in Ischemic Mice”, Journal of Stroke and Cerebrovascular Diseases, 2018, vol. 27, No. 11, pp. 3084-3094.
[cited by applicant]
JAPIC Clinical Trials; TMS-007; dated Jan. 26, 2018.
[cited by applicant]
Mican et al., “Structural Biology and Protein Engineering of Thrombolytics”, Computational and Structural Biotechnology Journal, 2019, vol. 17, pp. 917-938.
[cited by applicant]
Nikitin et al., “Development and Testing of Thrombolytics in Stroke”, Journal of Stroke, 2021, vol. 23, No. 1, pp. 12-36.
[cited by applicant]
Wardlaw et al., “Recombinant tissue plasminogen activator for acute ischemic stroke: an updated systematic review and meta-analysis”, The Lancet, 2012, vol. 379, No. 9834, pp. 2364-2372.
[cited by applicant]
Translation of Written Opinion issued in PCT/JP2020/044574 dated Jan. 26, 2021. (translation only- JP language document previously submitted).
[cited by applicant]
U.S. Appl. No. 17/106,862 Office Action dated Aug. 10, 2023.
[cited by applicant]
U.S. Appl. No. 17/106,862 Office Action dated Dec. 27, 2022.
[cited by applicant]
Matsumoto, Naoki et al. Soluble Epoxide Hydrolase as an Anti-inflammatory Target of the Thrombolytic Stroke Drug SMTP-7. The Journal of Biological Chemistry vol. 289,52: pp. 35826-35838 (2014).
[cited by applicant]